More Access and Evidence Articles

Access and Evidence

Unique Adaptive Trial Design Software Promises a Smoother Development of Clinical Trials

Anonymous, (Nov 21, 2012)

New adaptive trial design software ensures that pharmaceutical manufacturers can plan time and cost-effective clinical trials through extensive simulations.
Access and Evidence

Real World Series: Interview with Janssen

Jill Sackman, (Nov 16, 2012)

In this third installment of our Real World Data series, Jill Sackman speaks to Dr. Dell Kingsford Smith, Vice President, Global Pharmaceutical Pricing for Janssen about identification, implementation and potential pitfalls along the way.
Access and Evidence

Why the Surprise? In Emerging Markets, Price is Everything!

Craig Sharp, (Nov 15, 2012)

The patent revocation of Roche's hepatitis C drug Pegasys in India is just the latest in a long line of big pharma casualties within the area, and further underlines my growing belief that the “promise” of the emerging markets might be quickly fading away.
Access and Evidence

Emerging Markets: Not The Promised Land They Once Were?

Sophie Johnson, (Oct 26, 2012)

The announcement last week that India would no longer be licensing Fixed Dose Combination branded generics was another blow to big pharma's plans for the region, but does this signal a growing shift for all emerging markets?
Access and Evidence

Real World Series: Q&A with Jill Sackman

Craig Sharp, (Oct 24, 2012)

Real world evidence has become a topic of much discussion and debate in 2012, and over the coming weeks we are going to take an in-depth look at the promise, and advantages, shown by exciting new frontier in clinical data...
Access and Evidence

Innovation is Paramount: Choose to Outsource, Not Ignore R&D

Anonymous, (Oct 19, 2012)

AstraZeneca’s latest drug discovery partnership in China demonstrates the value of an early and innovative outsourced R&D effort in emerging markets.
Access and Evidence

Pricing Pfizer’s Xeljanz: An Opportunity for Change

Tony Brown, (Oct 18, 2012)

A newly published report highlights the therapeutic paradigm shift and opportunity for change presented by Pfizer's newest treatment for rheumatoid arthritis.
Access and Evidence

BRIC Broken? The End of Branded Drugs in India

Ben Steele, (Oct 17, 2012)

The Indian Health Ministry has made the game-changing announcement that its states are no longer to issue licenses for the manufacture or sale of branded drugs.
Access and Evidence

Q&A - Breaking Down The Wall: Market Access in China

Craig Sharp, (Sep 26, 2012)

We speek to Chia Wen Lee - Head of Emerging Markets Access for Biogen Idec - about the current landscape in lucrative China, the reality of the Essential Drugs List and the best approach for big pharma into this complex marketplace…
Access and Evidence

The Great Wall of China – Top 5 Barriers to Market Access

Ben Steele, (Sep 6, 2012)

Pharma expansion into emerging markets is not just desirable, but necessary to ensure continued growth, however both cultural and economic difference can often pose problems, here is our list of the top 5 barriers to entry into the Chinese marketplace.

Pages